13 Facts About Cipla

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India.

Cipla primarily develops medicines to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression and many other medical conditions.

In 1995, Cipla launched Deferiprone, the world's first oral iron chelator.

In 2001, Cipla offered antiretrovirals for HIV treatment at a fractional cost .

At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third biggest pharmaceutical company.

Related searches

Cipla had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd.

In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products, including escitalopram oxalate, lamivudine, and fluticasone propionate.

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.

Cipla cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

Equity shares of Cipla are listed on the Bombay Stock Exchange, where it is a constituent of the BSE SENSEX index, and the National Stock Exchange of India, where it is a constituent of the CNX Nifty.

The CEO of Cipla pressured the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs.

Since then Cipla has produced a low-cost drug to treat HIV, and expanded operations into several developing countries, including African nations, where most HIV and poor patients existed at one time.